

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on March 25, 2004 Date of Deposit Bonnie Stein Signature

Transmitted herewith for filing is the patent application

EL 964822445 US Express Mail No.

under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: ST01027US CNT

INVENTORS: F. Clerc, et al.

Substituted Benzimidazole TITLE:

Compounds and Their Use for the Treatment of

Cancer

ADDI ICATION EL EMENTO										
APPLICATION ELEMENTS										
1.	\boxtimes	*Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)								
2.		Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	Total Pages	156						
3.		Drawing(s) (35 U.S.C. 113)	Total Sheets	0						
4.	Oath a.	or Declaration Newly <u>unexecuted</u> (original or copy)	Total Pages	2						
	b.	Copy from a prior application (37 CFR § 1.	.63(d))							
		i. DELETION OF INVENTOR(S) Signed statement attached deleting i application, see 37 CFR §§ 1.63(d)(2)		ned in the prior						
5.	Powe	er of Attorney Newly executed (original or copy)	Total Pages							
	b.	Copy from a prior application (37 CFR § 1.	63(d))							
6.		Microfiche Computer Program (Appendix)								

Apr li Page	ication Transmittal Letter						
7.	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)						
	a. Computer Readable Copy						
	b. Paper Copy (identical to computer copy)						
	c. Statement verifying identity of above copies						
	If a CONTINUING Application, check appropriate box, and supply the requisite information: Continuation Divisional Continuation-in-part of prior application no: PCT/EP02/11353, filed September 26, 2002, Examiner, Group/Art Unit (The cross reference has been/will be inserted on page one of the specification).						
	This application claims the benefit of U.S. Provisional Application No. , filed . (The cross reference has been/will be inserted on page one of the specification).						
	Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.						
· ACC	COMPANYING APPLICATION PARTS						
7.	Assignment Papers (cover sheet & document(s))						
' 8.	37 CFR §3.73(b) Statement						
9.	(when there is an assignee) Verified English Translation Document (if applicable)						
9. 10.							
10.	Information Disclosure Copies of IDS Citations Statement (IDS)/PTO-1449						
11.	Preliminary Amendment						
12.	Return Receipt Postcard (MPEP 503)						
	(Should be specifically itemized)						
13.	*Small Entity Statement(s) Statement filed in prior application,						
	(PTO/SB/09-12) Status still proper and desired						
14.	Certified Copy of Priority Document(s) EP 01402460.8 (if foreign priority is claimed)						
15.	Other: Application Data Sheet						
COF	RRESPONDENCE ADDRESS						
\boxtimes	Customer Number or Bar Code Label 005487						
	(Insert Customer No. or Attach bar code label here)						
	Laurene J. Martin						
	Lawrence L. Martin, Reg. No. 46,902						
	Attorney/Agent for Applicant						

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4803
Telefax (908) 231-2626

Aventis Docket No. ST01027US CNT

PTO/SB/17 (01-03)
Approved for use through 04/30/2003. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL	Complete if Known				
LEE INAMOMITIAL	Application Number	Not Yet Assigned			
for EV 0004	Filing Date	Filed Concurrently Herewith	-		
for FY 2004	First Named Inventor	F. Clerc, et al.			
Patent fees are subject to annual revision.	Examiner Name	Not Yet Assigned			
Applicant claims small entity status. See 37 CFR 1.27	Group / Art Unit	Not Yet Assigned			
TOTAL AMOUNT OF PAYMENT (\$) 770.00	Attorney Docket No.	ST01027US CNT			

METHOD OF PAYMENT (check all that app	FEE CALCULATION (continued)						
Check Credit Card Money Other	3. Al	ODITIO	NAL FI	EES			
Order Deposit Account	Large E	ntity	Small E	ntity			
Deposit Account 19 1092		Fee Code	Fee (\$)	Fee Code	Fee (\$)		
Number 18-1982 Deposit	er 10-1302		(0)	0000	(4)	Fee Description	Fee Paid
Account Aventis Pharmaceuticals Inc.	1051	130	2051	65	Surcharge - late filing fee or oath		
The Commissioner is authorized to: (check all that ap						Surcharge - late provisional filing fee or	
Charge fee(s) indicated below Credit any overpaym	1052 1053	50 130	2052 1053	25 130	cover sheet Non-English Specification		
Charge any additional fee(s) during the pendency of this ap	plication	1812	2,520	1812	2,520	For filing a request for reexamination	
Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account	1804	920⁺	1804	920*	Requesting publication of SIR prior to Examiner action		
FEE CALCULATION	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action		
1. BASIC FILING FEE			110	2251	55	Extension for reply within first month	
Large Entity Small Entity Fee Fee Fee Fee Fee Description Code (\$) Code (\$)	Fee Paid	1252	420	2252	205	Extension for reply within second month	
1001 770 2001 375 Utility filing fee	770	1253	950	2253	465	Extension for reply within third month	
1002 340 2002 165 Design filing Fee		1254	1,480	2254	725	Extension for reply within fourth month	
1003 530 2003 260 Plant filing fee		1255	2,010	2255	985	Extension for reply within fifth month	
1004 770 2004 375 Reissue filing fee		1401	330	2401	160	Notice of Appeal	
1005 160 2005 80 Provisional filing fee		1402 1403	330	2402	160	Filing a brief in support of an appeal	
SUBTOTAL (1) (\$)770.00			290	2403	140	Request for oral hearing	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE			1,510	1451	1,510	Petition to institute a public use proceeding	
Fee Extra from	Fee	1452	110	2452	55	Petition to revive - unavoidable	
Claims below	Paid						
Total Claims 18 -20**= 0 x 18 =	0	1453	1,330	2453	650	Petition to revive - unintentional	
	0	1501	1,330	2501	650	Utility issue fee (or reissue)	
Claims		1502	480	2502	235	Design issue fee	
Multiple Dependent =		1503	640	2503	315	Plant issue fee	
Large Entity Small Entity		1460 1807	130 50	1460 1807	130 50	Petitions to the Commissioner Petitions related to provisional	
Fee Fee Fee		1001	00	1007		applications	
Code (\$) Fee Description 1202 18 2202 9 Claims in excess of 20		1806	180	1806	180	Submission of Information Disclosure Stmt	
1201 86 2201 42 Independent claims in exce	ess of 3	8021	40	8021	40	Recording each patent assignment per	
1203 290 2203 140 Multiple dependent claim, i	f not	1809	770	2809	375	property (times number of properties) Filing a submission after final rejection (37 CFR § 1.129(a))	
1204 86 2204 42 **Reissue independent claims over original pater	.	1810	770	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1205 18 2205 9 **Reissue claims in excess 20 and over original pater	of	1801	770	2801	375	Request for Continued Examination (RCE)	
	[1802	900	1802	900	Request for expedited examination of a design application	
SUBTOTAL (2) (\$)0		Other fee	(specify)				
**or number previously paid, if greater; For Reissues, see above	,	*Reduce	d by Basic	Filing Fee	Paid	SUBTOTAL (3) (S)	

SUBMITTED BY Complete (If applicable)							
Name (Print/Type)	Lawrence L. Martin, Reg. No. 46,902	Registration No. (Attorney/Agent)	46,902	Telephone	(908) 231-4803		
Signature	Laurence Z. Frantin			Date	3/25/04		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313. VA 22313-1450.

with the